Abstract. Castleman's disease (CD) is an uncommon lymphoproliferative disorder, which mostly occurs in the chest and neck. Lesions originating in the pelvic retroperitoneum are rare. It is important to consider CD as a differential diagnosis when a pelvic lesion is found. The present study reports a unique case of CD in the pelvic retroperitoneum, where the tumor was demonstrated to have a highly vascular nature on CT scanning. The preoperative diagnosis was uncertain and a vascular-derived tumor was considered. Laparoscopic surgery was performed and the mass was completely resected along with regional lymphadenectomy. The pathological diagnosis was the hyaline vascular type of CD. The patient was free of recurrence after 1 year of follow-up. As the underlying etiology remains elusive and the differential diagnosis is challenging preoperatively, surgical excision is the preferred treatment strategy for this type of benign lesion.

Introduction

Castleman's disease (CD), which was first described by Castleman and Towne (1) in 1954, is a rare lymphoproliferative disorder. The incidence rate of all forms of CD is estimated at 21–25 per million person-years, based on insurance registries in the USA (2). CD most commonly affects the mediastinum (63%), followed by the abdomen (11%), retroperitoneum (7%) and axilla (4%) (3). Based on the anatomical distribution of the disease, CD may be classified into two types: Unicentric and multicentric. Usually, ~25% of cases are unicentric (4). Unicentric CD (UCD) presents with isolated lymphadenopathy, usually detected in the chest and neck and less commonly in abdominal nodes or as a retroperitoneal mass (5). Localization of UCD in the pelvic retroperitoneum is rare, which accounts for 6.7% of UCD cases in the retroperitoneum (6). Diagnosis in this setting is difficult due to the lack of characteristic features on radiographic images. Most previous cases were diagnosed based on postoperative pathological examination (7). Given their proximity to major vascular structures of the pelvis, surgeons were occasionally faced with a clinical situation in which a large-volume blood transfusion was necessary (8). Thus, certain surgeons used preoperative angiography and embolization of the feeding arteries to the tumor in order to prevent or limit intraoperative bleeding (9). The present study reported a rare case of UCD located in the pelvic retroperitoneum, which was completely resected with meticulous laparoscopic surgery with limited bleeding. Although preoperative diagnosis was difficult to achieve, CD should be included in the differential diagnoses when a pelvic lesion is found.

Case report

CT scan. A 320-row spiral CT (uCT960+; Lianying) was used with the following parameters: Tube voltage, 100 kV; automatic tube current; thickness, 5.00 mm; pitch, 0.9937; rotation time, 0.8 sec/rot. The non-ionic contrast medium (Omnipaque 300 mg/ml; Cytiva) at the dose of 1.0 ml/kg was injected with a power injector at a rate of 3.0 ml/sec through the median cubital vein. This was followed by flushing with 20 ml saline at a rate of 3.0 ml/sec. The arterial and venous phases were obtained at 25 to 30 sec and 60 to 75 sec after the injection of the contrast medium.

Histopathological staining. Formalin-fixed paraffin-embedded (FFPE) sections were cut with a Leica RM 2155 Rotary Microtome (Leica Microsystems) and the paraffin sections were then dewaxed sequentially with xylene, anhydrous ethanol, a decreasing concentration gradient of ethanol (95, 90, 80 and 70%) and water. Slices were immersed in Harris hematoxylin staining solution for 5 min and then differentiated with 0.3% acid alcohol, followed by incubation with 0.6% ammonia. Subsequently, samples were incubated with eosin staining solution for 1-3 min and then dehydrated with ethanol and xylene, and finally, slides were mounted with neutral gum.
Diagnostics), which comprised horseradish peroxidase-conju-}

gated rabbit secondary antibodies, DAB CM and H2O2:CM
generated, increasing concentrations of xylene and then

tempered with coverslips. Monoclonal primary anti-

genes were blocked with Inhibitor CM included in the iVIEW DAB

test was performed in Tris-EDTA buffer (pH 7.8 at 95°C for 40 min),

to CD21, CD3, CD20 and CD34 were purchased from

Inhibitor CM and Inhibitor CM according to the manufacturer's instructions. The slides were

to the cervical, clavicular or inguinal zones. Laboratory parameters were all normal. Preoperative CT

A total of three histological types of CD have been identi-

isolated, ligated and divided. The vein of the tumor entered the

The resected tumor was rubbery, firm and well circum-

test was performed in Tris-EDTA buffer (pH 7.8 at 95°C for 40 min),

to be reactive hyperplasia on microscopy. (HHV-8) was negative. The resected enlarged lymph node was

Discussion

CD describes a rare group of lymphoproliferative disorders with characteristic histopathologic appearances (10), the etiology of which remains to be fully elucidated. This disease includes unicentric and multicentric forms, which are thought to represent distinct clinical entities with different patient characteristics, presentation, treatment responses and long-term outcomes (4). UCD presents with isolated lymphadenopathy, usually diagnosed in the fourth decade of life. It is frequently found incidentally due to a lack of symptoms and benign course (11). By contrast, multicentric CD (MCD) presents with the enlargement of multiple lymph nodes, usually accompanied by mild to life-threatening symptoms such as fatigue, fever, weight loss, anemia, sweat, splenomegaly, dyspnea and pulmonary fibrosis (12,13). The presentation of MCD may occasionally be associated with HIV infection, Kaposi's sarcoma and POEMS symptoms (peripheral sensorimotor neuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin lesions) (14). MCD usually develops later in the fifth and sixth decades of life, with an estimated 5-year overall survival of ~65% (11).

Although the underlying etiology of CD remains to be established, excessive secretion of the cytokine interleukin-6 (IL-6) is thought to contribute to numerous symptoms associated with MCD (15). Certain cases of MCD have been attributed to HHV-8 infection in immunosuppressed patients. Viral IL-6, human IL-6 and several other proinflammatory proteins are thought to be involved in the pathogenesis of HHV-8-associated MCD (16). In patients with HHV-8-negative idiopathic MCD, a separate malignant disease may be found to co-exist, suggesting a common genetic mutation may be a contributor (17).

A total of three histological types of CD have been identified: Hyaline vascular, plasma cell and the mixed variant. The hyaline vascular type is most commonly seen in UCD, characterized by an increased number of lymphoid follicles
with degenerative germinal centers and broad mantle zones composed of concentric rings of small lymphoid cells ('onion skin pattern'). Germinal centers are predominantly composed of follicular dendritic cells, penetrated by sclerotic hyalinized vessels ('lollipop lesions'). By contrast, the plasma cell type most commonly occurs in MCD, characterized by the presence of sheets of plasma cells in the interfollicular zone and hyperplastic germinal centers (18). In the present case, prominent vascular proliferation and hyalinization of the vessel walls were obvious with a lack of an 'onion skin pattern' appearance. Germinal centers were degenerative, consisting of follicular dendritic cells marked with CD21 immunostain.

UCD in the pelvic retroperitoneum is rare and the preoperative diagnosis is difficult due to its low frequency and lack of characteristic features on radiographic images (7). Similar to lymphoma, CT scans display homogenous enhancement of the lesions if they are smaller than 5 cm. Calcification may also be seen in up to 31% of cases (19). In the present case, the tumor was homogenously enhanced without calcification. However, it is important to consider the possibility of pelvic CD in the differential diagnosis of a calcified pelvic tumor. Positron emission tomography (PET)/CT is thought to be helpful for distinguishing CD from lymphoma. When difficulties are encountered, biopsy of the site with the highest standardized uptake value (SUV) is recommended (5).

The differential diagnosis of UCD includes lymphoma, sarcoma, lymph node metastasis, gastrointestinal stromal tumor, lipomas, leiomyomas, neurofibromas, paraganglioma and infectious diseases (20). It is challenging to differentiate UCD from lymphoma preoperatively. The lymphadenopathy of UCD is unifocal and the swollen node is commonly larger than the size of lymphoma lymph nodes (4). Furthermore, when PET/CT is performed, the median maximum SUV is typically

Figure 1. Preoperative CT scan of the pelvis. (A) Retroperitoneal tumor located on the left of the bladder with a remarkable contrast effect (arrow). (B) Arterial supply to the tumor arose from branches of the left external iliac artery (thin arrow), with venous drainage entering the left external iliac vein (thick arrow). (C) An enlarged lymph node was located lateral to the left external iliac artery (arrow).

Figure 2. Laparoscopic and macroscopic findings of pelvic retroperitoneal Castleman's disease. (A) The tumor was well-circumscribed with the feeding artery originating from the pubic branch of the left inferior epigastric artery (thin arrow) and the vein entered the left external iliac vein (thick arrow). (B) Image of the excised tumor. The capsule of the tumor was thickened (arrow).
ZHAO et al: CASTLEMAN’S DISEASE IN PELVIS

As mentioned above, core biopsy of the tumor may be helpful to distinguish the two entities.

In the present case, given the highly vascular nature of the tumor, biopsy was not performed, as the mass was thought to be derived from great vessels, which may have possibly led to bleeding and increased the difficulty of subsequent surgical procedures. Furthermore, the diagnosis of CD requires a pathological review of the affected lymph node, which should ideally be performed from an excisional biopsy, as the definitive diagnosis is mainly based on cell architecture (21).

MCD requires systemic treatment and individualized strategies on the basis of different subtypes (14). Surgery is reserved to obtain tissue for a full histopathologic diagnosis (4). By contrast, complete surgical resection has been considered the gold standard treatment in patients with UCD (4). Challenges may be encountered during resection of UCD in the pelvis due to its proximity to major vessels and adhesions. Hypervascularity is frequently associated with UCD at excision, increasing the risk of vascular injury and blood transfusion (8). To avoid massive hemorrhage, as observed in the present case, meticulous dissection around the tumor and slight traction were required to expose the feeding vessels. A detailed review of CT scans served a paramount role in the scheduled step-by-step procedures during laparoscopic surgery. Although no evidence of local recurrence or systemic disease was detected during 1 year of follow-up, long-term follow-up is required, as a rare recurrence has been reported in the literature (22).

In summary, the present study reported a rare case of UCD in the pelvic retroperitoneum in a male patient, which was treated successfully by complete resection of the tumor. A definitive diagnosis was not accomplished until histological analysis was performed. Meticulous dissection should be warranted to minimize hemorrhage during laparoscopic surgery. Surgical resection is the gold standard treatment strategy for this neoplasm and long-term follow-up is needed to detect any recurrence.

Acknowledgements
Not applicable.

Funding
This work was supported by the Shandong Medical and Health Science and Technology Development Plan Project (grant no. 2019WS510).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors’ contributions
SH was the principal responsible person for the study and contributed to the conception and the design of the study. QZ and XZ obtained and analyzed the patient’s information and contributed to manuscript drafting and critical revisions of the intellectual content. XY performed the histological examination of the tumor and lymph node. QZ, XZ, XY and SH confirmed the authenticity of all the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate
All procedures were approved by the ethics committee of the First Affiliated Hospital of Shandong First Medical University (Jinan, China; approval no. 2022S478).

~3-8, whereas higher values would suggest lymphoma (5). As mentioned above, core biopsy of the tumor may be helpful to distinguish the two entities.

In the present case, given the highly vascular nature of the tumor, biopsy was not performed, as the mass was thought to be derived from great vessels, which may have possibly led to bleeding and increased the difficulty of subsequent surgical procedures. Furthermore, the diagnosis of CD requires a pathological review of the affected lymph node, which should
Patient consent for publication

The publication of the article was with the written informed consent of the patient.

Competing interests

The authors declare that they have no competing interests.

References

1. Castleman B and Towne VW: Case records of the massachusetts general hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N Engl J Med 251: 396-400, 1954.

2. Munshi N, Mehra M, van de Velde H, Desai A, Potluri R and Vermeulen J: Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma 56: 1252-1260, 2015.

3. Bacher P, Chassot G, Zufferey G, Ris F, Huber O and Morel P: Surgical management of abdominal and retroperitoneal Castleman's disease. World J Surg Oncol 3: 33, 2005.

4. Talat N, Belgaumkar AP and Schulte KM: Surgery in castleman's disease a systematic review of 404 published cases. Ann Surg 255: 677-684, 2012.

5. Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, Vercellino L, Meignin V, Gérard L and Galicier L: The full spectrum of castleman disease: 273 patients studied over 20 years. Br J Haematol 180: 206-216, 2018.

6. Gopi P, Potty VS, Kaurav RS and Govindan K: Unicentric Castleman's disease as a localized retroperitoneal mass: A case report and review of literature. Int J Appl Basic Med Res 8: 259-262, 2018.

7. Nakata K, Iwashashi N, Matsukawa H, Noguchi T, Yahata T, Ota N, Makushik Y and Ino K: Laparoscopically resected castleman's disease in the pelvic retroperitoneum: A case report. Mol Clin Oncol 12: 169-173, 2020.

8. Nepal SP, Shichijo T, Ogawa Y, Naoe M, Oshinomi K and Morita J: Surgical challenges of Castleman's disease of the pelvis. Urol Case Rep 34: 101518, 2020.

9. Kitakaze M, Miyoshi N, Fujino S, Ogino T, Takahashi H, Uemura M, Mizushima T, Doki Y and Eguchi H: Surgical resection for pelvic retroperitoneal Castleman's disease: A case report and review literature. Biomed Rep 14: 29, 2021.

10. Szalat R and Munshi NC: Diagnosis of castleman disease. Hematol Oncol Clin North Am 32: 53-64, 2018.

11. Dispenzieri A, Armitage JO, Loe MJ, Geyer SM, Allred J, Camoriano JK, Menke DM, Weisenburger DD, Ristow K, Dogan A and Habermann TM: The clinical spectrum of Castleman's disease. Am J Hematol 87: 997-1002, 2012.

12. Yu LI, Tu M, Cortes J, Xu-Monette ZY, Miranda RN, Zhang J, Orlowski RZ, Neelapu S, Boddu PC, Akosile MA, et al: Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood 129: 1658-1668, 2017.

13. Murakami M, Johkoh T, Hayashi S, Ohshima S, Mizuki M, Nakatsuka SI, Tomobe M, Kurayamagi K, Nakasono A and Nishimoto N: Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan. Mod Rheumatol 30: 843-851, 2020.

14. Lomas OC, Streeth M, Pratt G, Cavet J, Royston D, Schey S and Ramasamy K; British Society for Haematology (BSH) Committee: The management of Castleman disease. Br J Haematol 195: 328-337, 2021.

15. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Azazza K, Nakahata T, Kawai H, Tagoh H, Komori T, et al: Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74: 1360-1367, 1989.

16. Suthaus J, Stuhlmann-Laesicz C, Tompkins VS, Rosean TR, Klapper W, Tosato G, Janz S, Scheller J and Rose-John S: HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood 119: 5173-5181, 2012.

17. Liu AY, Nabel CS, Finkelstein BS, Ruth JR, Kurzrock R, van Rhee F, Krymskaya VP, Kelleher D, Rubenstein AH and Fajgenbaum DC: Idiopathic multicentric Castleman's disease: A systematic literature review. Lancet Haematol 3: e163-e175, 2016.

18. Dispenzieri A and Fajgenbaum DC: Overview of Castleman disease. Blood 135: 1353-1364, 2020.

19. Meador TL and McLarney JK: CT features of Castleman's disease of the abdomen and pelvis. AJR Am J Roentgenol 175: 115-118, 2000.

20. Jiang Y, Hou G, Zhu Z, Huo L, Li F and Cheng W: The value of multiparameter 18F-FDG PET/CT imaging in differentiating retroperitoneal paragangliomas from unicentric Castleman disease. Sci Rep 10: 12887, 2020.

21. Carbone A, Borok M, Damania B, Gloghini A, Polizzotto MN, Jayanthan RK, Fajgenbaum DC and Bower M: Castleman disease. Nat Rev Dis Primers 7: 84, 2021.

22. Ren N, Ding L, Jia E and Xue J: Recurrence in unicentric Castleman's disease postoperatively: A case report and literature review. BMC Surg 18: 1, 2018.